Document is current
Any future updates will be listed below
-
Authors
Yap, Timothy A
Bessudo, Alberto
Hamilton, Erika
Sachdev, Jasgit
Patel, Manish R
Rodon, Jordi
Evilevitch, Lena
Duncan, Meghan
Guo, Wei
Kumar, Sujatha
Lu, Sharon
Dezube, Bruce J
Gabrail, Nashat
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03307785 at ClinicalTrials.govnct02657889 at ClinicalTrials.govDocuments that mention this clinical trial
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003924
nct03307785 at ClinicalTrials.govDocuments that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Potentiation of cancer immunogenicity by targeting PARP
https://doi.org/10.1136/jitc-2024-011056
The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers
https://doi.org/10.1136/ijgc-2020-001789
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option
https://doi.org/10.1136/ijgc-2019-000624
92 High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlatives of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0092
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003924
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003924
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
